S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS
Main Authors: | Yi Zhang, Hu Zhou, Junling Zhuang, Aili He, Yarong LI, Linhua Yang, Xin Du, Sujun Gao, Guangsheng He, Mei Hong, Qian Jiang, Zhongxing Jiang, Sun Kai, Lingling Yue, Cuiping Zheng, Zeping Zhou, Chenghao Jin, Hongmei Jing, Lin Liu, Qingchi Liu, Jishi Wang, Wen Wu, Yajing Xu, Dengshu Wu, Na Xu, Feng Zhang, Jin Zhang, Huanling Zhu, Zhijian Xiao, Jie Jin |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000967760.70775.53 |
Similar Items
-
P1021: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE INTOLERANT TO RUXOLITINIB: AN OPEN-LABEL, SINGLE-ARM PHASE 2B STUDY
by: Yi Zhang, et al.
Published: (2023-08-01) -
P1033: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE REFRACTORY OR RELAPSED TO RUXOLITINIB: A SINGLE-ARM, OPEN-LABEL, MULTICENTER, PHASE 2 STUDY
by: Yi Zhang, et al.
Published: (2023-08-01) -
Hydroxyurea-induced melanonychia
by: Michael G. Buontempo, BS, et al.
Published: (2023-12-01) -
Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01) -
Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01)